诺和诺德股价周三盘中大涨5.06%,引发市场广泛关注。公司刚刚公布的2024财年第四季度业绩显示,营收和利润均大幅超出市场预期。
具体来看,诺和诺德第四季度销售额同比增长30%,达到856.83亿丹麦克朗,高于分析师预期7.47%。公司每股收益达6.34丹麦克朗,同比增长29.12%,也超过了预期8.93%。由于数据表现强劲,诺和诺德全年净利润达到1009亿丹麦克朗,超过预期。
值得一提的是,诺和诺德销售额的大幅增长主要得益于其减重版司美格鲁肽注射液Wegovy的销售额超过预期。数据显示,第四季度Wegovy销售额达到198.7亿丹麦克朗,按固定汇率计算同比大涨107%,充分体现出了市场对此类减重新药的强劲需求。分析人士普遍看好诺和诺德在未来可期待的更大的肥胖症治疗市场。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.